Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$2.02 +0.50%

+$0.01 today

Market cap
$191.34M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.20M

Average 0.48M

CGEN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Compugen Ltd.NASDAQ: CGEN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $6.94M rose 20.2% year over year, ahead of the -1.0% change in trailing-twelve-month research & development. Sequentially, it rose 25.1% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.

Context

  • Research & development amounted to 31.3% of revenue in FY2025, down 57.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.2% holds above the trailing-twelve-month pace of -1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.94M+25.1% QoQ
Last fiscal yearDec 2025
$22.76M-8.3% YoY
LTMMar 2026
$23.92M-1.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.2%——
1 year-8.3%——
3-year CAGR-9.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
22.76M USD
Year-over-year change
-8.3%
4-year CAGR
-5.6%

Research & Development vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.0% is the 5th highest of 9, against a peer median of +1.9%.
  • Research & development amounts to 32.9% of revenue for CGEN, versus a peer median of 928.4%.
CGEN Competitors
Research & Development for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$55.26M USD+60.0%-18.4%314.8%
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
IPHAInnate Pharma S.A.FY2025€43.62M EUR-16.1%-5.5%1565.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
CGENCompugen Ltd.LTM Mar 2026$23.92M USD-1.0%-9.4%32.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$18.8M USD-26.8%-18.0%593.1%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$18.58M USD+33.3%+11.1%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding CGEN) —+1.9%-6.5%928.4%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$2.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.